Open access
Open access
Powered by Google Translator Translator

Urology

SR | Management of lymph node–positive penile cancer

24 May, 2023 | 13:03h | UTC

Management of Lymph Node–positive Penile Cancer: A Systematic Review – European Urology

 


Epidemiology of bladder cancer in 2023: a systematic review of risk factors

22 May, 2023 | 13:23h | UTC

Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors – European Urology

 


Fluorescence-guided surgery: comprehensive review

18 May, 2023 | 13:34h | UTC

Fluorescence-guided surgery: comprehensive review – BJS Open

 

Commentary on Twitter

 


A review of modern imaging landscape for prostate cancer: a comprehensive clinical guide

9 May, 2023 | 14:34h | UTC

A Review of Modern Imaging Landscape for Prostate Cancer: A Comprehensive Clinical Guide – Journal of Clinical Medicine

 


21-y clinical trial update | Effects of a PSA–based screening on morbidity and mortality of prostate cancer

5 May, 2023 | 14:56h | UTC

A Detailed Evaluation of the Effect of Prostate-specific Antigen–based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer – European Urology

 


AUA/SUO Guideline | Part I – Early detection of prostate cancer: prostate cancer screening

2 May, 2023 | 13:49h | UTC

Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening – The Journal of Urology

See also: Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy – The Journal of Urology

 


AUA/SUO Guideline | Part II – Early detection of prostate cancer: considerations for a prostate biopsy

2 May, 2023 | 13:47h | UTC

Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy – The Journal of Urology

See also: Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening – The Journal of Urology

 


AUA/SUO Guideline | Updates to Advanced Prostate Cancer

2 May, 2023 | 13:46h | UTC

Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023) – The Journal of Urology

 


AUA/SUO Guideline | Diagnosis and management of non-metastatic upper tract urothelial carcinoma

2 May, 2023 | 13:44h | UTC

Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline – The Journal of Urology

 


AUA/SUFU Guideline | Updates to surgical treatment of female stress urinary incontinence

2 May, 2023 | 13:43h | UTC

Updates to Surgical Treatment of Female Stress Urinary Incontinence (SUI): AUA/SUFU Guideline (2023) – The Journal of Urology

 


Guideline | Urethral stricture disease

2 May, 2023 | 13:41h | UTC

Urethral Stricture Disease Guideline Amendment (2023) – The Journal of Urology

 


Single-arm trial | Retroperitoneal lymph node dissection as first-line treatment for early metastatic seminoma shows 81% 2-Year RFS

28 Apr, 2023 | 13:02h | UTC

Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy – Journal of Clinical Oncology

News Release: Surgery proves effective alternative to chemotherapy and radiation for early metastatic testicular cancer – Keck Medicine of USC

Commentary: Retroperitoneal Lymph Node Dissection for Early Metastatic Testicular Seminoma – The ASCO Post

 


Review | Risk stratification of low-risk prostate cancer: individualizing care in the era of active surveillance

25 Apr, 2023 | 14:35h | UTC

Risk Stratification of Low-Risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance – Journal of Urology (free PDF for a limited period)

Related:

Low-Value Prostate-Specific Antigen Screening in Older Males – JAMA Network Open

RCT | Patient-reported outcomes 12 years after different treatments for localized prostate cancer

RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes

 


Brief Review | Investigation and assessment of adrenal incidentalomas

25 Apr, 2023 | 14:13h | UTC

Investigation and assessment of adrenal incidentalomas – Clinical Medicine Journal

 


M-A | 5-alpha-reductase inhibitors are not associated with increased risk of mortality from prostate cancer

24 Apr, 2023 | 13:30h | UTC

Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality: A Systematic Review and Meta-analysis – JAMA Oncology (free for a limited period)

 

Commentary on Twitter

 


ASCO Guideline Update | Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer

18 Apr, 2023 | 12:54h | UTC

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update – Journal of Clinical Oncology

 


RCT | MRI–guided vs CT–guided stereotactic body radiotherapy for prostate cancer

18 Apr, 2023 | 12:52h | UTC

Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial – JAMA Oncology

News Release: MRI-guided radiotherapy produces fewer side effects and better quality of life for patients with localized prostate cancer – University of California – Los Angeles Health Sciences

 


RCT | Doxycycline postexposure prophylaxis effective in preventing gonorrhea, chlamydia, and syphilis in MSM

12 Apr, 2023 | 13:30h | UTC

Summary: In this open-label, randomized study involving 501 men who have sex with men (MSM) and transgender women, researchers investigated the effectiveness of postexposure doxycycline in preventing bacterial sexually transmitted infections (STIs), specifically gonorrhea, chlamydia, and syphilis. Participants with a previous STI in the past year, either taking preexposure prophylaxis (PrEP) against HIV or living with HIV, were randomly assigned to receive 200 mg of doxycycline within 72 hours after condomless sex or standard care without doxycycline. STI testing was performed quarterly, with the primary end point being the incidence of at least one STI per follow-up quarter.

Results demonstrated a significant reduction in STI incidence in both the PrEP and persons living with HIV cohorts who received doxycycline.  Overall, the combined incidence of these three STIs was lower by two thirds with doxycycline postexposure prophylaxis compared to standard care. The study also reported five grade 3 adverse events but no serious adverse events attributed to doxycycline. This finding supports the use of doxycycline postexposure prophylaxis among MSM with recent bacterial STIs.

Article: Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Doxycycline after sex found to reduce STI incidence in gay men, transgender women – CIDRAP

 

Commentary on Twitter

 


RCT | Effects of focal vs. extended irreversible electroporation ablation of localized prostate cancer

12 Apr, 2023 | 13:05h | UTC

Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)

Commentary: Focal vs Extended Irreversible Electroporation in Ablation of Localized Low- or Intermediate-Risk Prostate Cancer – The ASCO Post

 

Commentary on Twitter

 


Phase 2 RCT | Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer

10 Apr, 2023 | 13:41h | UTC

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial – JAMA Oncology (free for a limited period)

 

Commentary on Twitter

 


Review | Urinary incontinence and pelvic organ prolapse in women

10 Apr, 2023 | 13:27h | UTC

Urinary Incontinence and Pelvic Organ Prolapse in Women: Prevention and Treatment – Deutsches Ärzteblatt International

 


ESMO Guideline | Updated treatment recommendations for prostate cancer

6 Apr, 2023 | 13:18h | UTC

Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents – Annals of Oncology

 


Guideline | Muscle-invasive and metastatic bladder cancer

6 Apr, 2023 | 13:19h | UTC

Muscle-invasive and Metastatic Bladder Cancer – European Association of Urology (see PDF)

 


Consensus Paper | Treatment of sexual dysfunction after surgery for prostate cancer

22 Mar, 2023 | 13:34h | UTC

Consensus of Experts on the Treatment of Sexual Dysfunction after Surgery for Prostate Cancer in Taiwan – Journal of Clinical Medicine

 


RCT | Patient-reported outcomes 12 years after different treatments for localized prostate cancer

15 Mar, 2023 | 15:24h | UTC

Summary: The article reports on a study that evaluated patient-reported outcomes of 1,643 participants in the ProtecT trial over a period of 7 to 12 years to assess the long-term functional and quality-of-life impacts of prostatectomy, radiotherapy with neoadjuvant androgen deprivation, and active monitoring for localized prostate cancer detected by PSA screening.

The study found that generic quality-of-life scores were similar among the randomized groups over 7 to 12 years. However, although the prostatectomy group had a lower incidence of nocturia, they showed a higher incidence of urinary incontinence and sexual dysfunction compared to the radiotherapy and active monitoring groups. The radiotherapy group had a higher incidence of fecal leakage compared to the other groups.

The study provides evidence that helps patients and their clinicians assess the trade-offs between treatment harms and benefits and make better-informed treatment decisions.

Article: Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment – NEJM Evidence

Original Study: RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts US$ 7.00/month

No spam, just news.